| abstract |
The present invention provides tissue plasminogen activator antibody molecules and uses thereof. More specifically, the disclosed invention provides humanized antibody molecules that specifically bind Tissue Plasminogen Activator (TPA) and their use to treat TPA-induced bleeding, particularly systemic bleeding such as cerebral bleeding after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke, or myocardial infarction. |